Transaction DateRecipientSharesTypePriceValue
19th October 2020John Gordon Freund190,053Open or private sale$22.00$4,181,166.00
5th October 2020Trevor Hallam9,182Exercise of derivative$4.36$40,033.52
28th September 2020Trevor Hallam975Open or private sale$10.26$10,006.72
25th September 2020Trevor Hallam2,381Payment by withholding$10.30$24,524.30
25th September 2020William J Newell13,219Payment by withholding$10.30$136,155.70
25th September 2020Trevor Hallam11,019Exercise of derivative$0.00
25th September 2020William J Newell25,252Exercise of derivative$0.00
25th September 2020Arturo Md Molina2,976Payment by withholding$10.30$30,652.80
25th September 2020Arturo Md Molina8,609Exercise of derivative$0.00
25th September 2020Trevor Hallam3,810Payment by withholding$10.30$39,243.00
Sutro Biopharma
Sutro Biopharma logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.


Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility.


Ticker: STRO
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1382101
Employees: 168
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $65 M (0%)
Marketable Securities, Current: $136 M (20%)
Assets, Current: $258 M (101%)
Property, Plant and Equipment, Net: $11 M (16%)
Other Assets, Noncurrent: $2 M (-16%)
Assets: $278 M (77%)
Accounts Payable, Current: $5 M (-12%)
Accrued Liabilities, Current: $5 M (-24%)
Liabilities, Current: $35 M (7%)
Long-term Debt, Excluding Current Maturities: $24 M (173%)
Other Liabilities, Noncurrent: $148 Th (10%)
Liabilities: $71 M (20%)
Common Stock, Value, Issued: $36 Th (56%)
Common Stock, Shares, Issued: $36 M (55%)
Additional Paid in Capital, Common Stock: $392 M (33%)
Retained Earnings (Accumulated Deficit): $185 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $398 Th (141%)
Stockholders' Equity (Parent): $207 M (0%)
Liabilities and Equity: $278 M (77%)
Revenue: $9 M (-43%)
Research and Development: $17 M (-50%)
General and Administrative Expenses: $9 M (-50%)
Operating Income/Loss: $16 M (-53%)
EPS (basic): $1 (0%)
EPS (diluted): $0.94 (0%)